Global Transdermal Drug Delivery Systems Market Report, 2019 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Transdermal Drug Delivery Systems Market Analysis 2019” report has been added to ResearchAndMarkets.com’s offering.

The Global Transdermal Drug Delivery Systems market is expected to reach $9.29 billion by 2026 growing at a CAGR of 6.3% during the forecast period.

Increasing prevalence of chronic diseases, technological advancements in transdermal drug delivery systems, and growing geriatric population along with the rise in prevalence of chronic diseases across the world are some of the factors fuelling the market growth. However, disadvantages of delivery systems including edema and irritation, natural limits of drug entry imposed by the skin’s impermeability, and lack of adhesion of the transdermal system to different skin types are hampering the market growth.

Based on the application, the pain management segment is likely to have a huge demand due to elevating burden of chronic pain globally and the growing availability of transdermal products for pain management.

The key vendors mentioned are UCB S.A., Hisamitsu Pharmaceutical Co., Inc., Glaxosmithkline PLC, Johnson & Johnson (J&J), Mylan N.V., Boehringer Ingelheim International GmbH, Novartis AG, Lavipharm, Endo International, Inc., Luye Pharma Group, Purdue Pharma L.P., Lead Chemicals Co., Inc., Pfizer Inc., Allergan Plc, Actelion Pharmaceuticals Ltd, Noven Pharmaceuticals, Inc., Echo Therapeutics, Inc., Boehringer Ingelheim Gmbh, Bayer Ag, and Acrux Limited.

Key Questions Answered in this Report

  • How this market evolved since the year 2016
  • Market size estimations, forecasts and CAGR for all the segments presented in the scope
  • Key Market Developments and financials of the key players
  • Opportunity Analysis for the new entrants
  • SWOT Analysis of the key players
  • Fastest growing markets analysed during the forecast period

Key Topics Covered

1 Market Synopsis

2 Research Outline

2.1 Research Snapshot

2.2 Research Methodology

2.3 Research Sources

2.3.1 Primary Research Sources

2.3.2 Secondary Research Sources

3 Market Dynamics

3.1 Drivers

3.2 Restraints

4 Market Environment

4.1 Bargaining power of suppliers

4.2 Bargaining power of buyers

4.3 Threat of substitutes

4.4 Threat of new entrants

4.5 Competitive rivalry

5 Global Transdermal Drug Delivery Systems Market, By Technology

5.1 Introduction

5.2 Electroporation

5.3 Electric Current

5.4 Ultrasound

5.5 Iontophoresis

5.6 Microporation

5.7 Sonophoresis

5.8 Thermal

5.9 Radiofrequency

5.10 Mechanical Arrays

5.11 Other Technologies

6 Global Transdermal Drug Delivery Systems Market, By Product Type

6.1 Introduction

6.2 Nitroglycerin

6.3 Nicotine

6.4 Fentanyl

6.5 Other Product Types

7 Global Transdermal Drug Delivery Systems Market, By Type

7.1 Introduction

7.2 Transdermal Semisolids/Active

7.3 Transdermal Patches/Passive

8 Global Transdermal Drug Delivery Systems Market, By Application

8.1 Introduction

8.2 Hormonal Applications

8.3 Cardiovascular Diseases

8.4 Central Nervous System Disorders

8.5 Pain Management

8.6 Smoking Cessation

8.7 Contraception

8.8 Analgesics

8.9 Motion Sickness

8.10 Hypertension

9 Global Transdermal Drug Delivery Systems Market, By End-user

9.1 Introduction

9.2 Hospitals & Clinics

9.3 Home Care Settings

9.4 Surgical Centers

9.5 Other End-users

10 Global Transdermal Drug Delivery Systems Market, By Geography

10.1 Introduction

10.2 North America

10.3 Europe

10.4 Asia-Pacifc

10.5 South America

10.6 Middle East & Africa

11 Strategic Benchmarking

12 Vendors Landscape

12.1 UCB S.A.

12.2 Hisamitsu Pharmaceutical Co. Inc.

12.3 Glaxosmithkline PLC

12.4 Johnson & Johnson (J&J)

12.5 Mylan N.V.

12.6 Boehringer Ingelheim International GmbH

12.7 Novartis AG

12.8 Lavipharm

12.9 Endo International, Inc.

12.10 Luye Pharma Group

12.11 Purdue Pharma L.P.

12.12 Lead Chemicals Co. Inc.

12.13 Pfizer Inc.

12.14 Allergan PLC

12.15 Actelion Pharmaceuticals Ltd.

12.16 Noven Pharmaceuticals, Inc.

12.17 Echo Therapeutics, Inc.

12.18 Boehringer Ingelheim GmbH

12.19 Bayer AG

12.20 Acrux Limited

For more information about this report visit https://www.researchandmarkets.com/r/hqpoll



Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.